What's New

News

Nippon Kayaku's news releases are issued to inform our stakeholders of the latest information regarding the Company.
While some news releases may contain information about pharmaceutical products (including those under development), they are intended solely for disclosure purposes to members of the media, shareholders, and investors, and are not intended for advertising or promotional purposes, nor to provide medical advice.

2023/10/19
Updated information of sustainability
2023/10/18
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
2023/09/25
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody. PDF
2022/11/16
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody PDF
2021/06/30
New Late-Breaking Data at The American Diabetes Association Show GlycoMark May Be an Effective Test for COVID-19 Severity PDF
PageTop
Our Business
R&D
Corporate Information
Global Network
Investor Relations
Integrated report
Sustainability